Gegenava Maka, Gegenava Tea
Tbilisi State Medical University.
Sarcoidosis Vasc Diffuse Lung Dis. 2024 Mar 26;41(1):e2024023. doi: 10.36141/svdld.v41i1.14570.
Pulmonary hypertension (PH) is a frequent complication of connective tissue disorders (CTDs), with a major impact on the prognosis of the disease. The aim of our study was to perform a systemic review and meta-analysis of published literature evaluating survival function in patients with systemic sclerosis (SSc) with and without PH and to compare survival function between patients with SSc, systemic lupus erythematosus (SLE), other CTDs, and conditions associated with PH.
The established protocol of the Cochrane Collaboration Steps and meta-analysis of observational studies in epidemiology recommendations (MOOSE) were used.
7 studies, including 1470 SSc-PH patients and 1368 SSc patients without PH, and 4 studies, including 108 SLE-PH patients and 1288 SLE patients without PH, assessed survival function were selected. Six studies (including 777 SSc, 249 SLE, 90 idiopathic pulmonary arterial hypertension (IPAH) and 29 primary Sjogren's syndrome patients) comparing survival function in different subgroups of patients with confirmed PH were included. SSc patients with PH showed the worst survival as compared to SSc patients without PH [OR (95% CI) 3.70 (2.42-5.67); p<0.00001]. The same pattern was observed in patients with SLE. SSc patients with PH were characterized by lower survival function compared to other reasons for PH, including SLE [OR (95% CI) 2.76 (1.95-3.91); p<0.00001].
Patients with SSc-PH are characterized by significantly lower survival function as compared to SSc patients without PH. Among the different entities of PH, SSc shows the worst survival, underlining prognostic significance of detection and evaluation of PH according to the currently established approach.
肺动脉高压(PH)是结缔组织病(CTD)常见的并发症,对疾病预后有重大影响。我们研究的目的是对已发表的文献进行系统评价和荟萃分析,评估系统性硬化症(SSc)合并和不合并PH患者的生存功能,并比较SSc、系统性红斑狼疮(SLE)、其他CTD以及与PH相关疾病患者的生存功能。
采用Cochrane协作网步骤及流行病学观察性研究荟萃分析推荐意见(MOOSE)的既定方案。
选择了7项研究,包括1470例SSc-PH患者和1368例不合并PH的SSc患者,以及4项研究,包括108例SLE-PH患者和1288例不合并PH的SLE患者,这些研究评估了生存功能。纳入了6项研究(包括777例SSc、249例SLE、90例特发性肺动脉高压(IPAH)和29例原发性干燥综合征患者),比较了确诊为PH的不同亚组患者的生存功能。与不合并PH的SSc患者相比,合并PH的SSc患者生存率最差[比值比(95%置信区间)3.70(2.42 - 5.67);p<0.00001]。SLE患者也观察到同样的模式。与包括SLE在内的其他PH病因相比,合并PH的SSc患者生存功能较低[比值比(95%置信区间)2.76(1.95 - 3.91);p<0.00001]。
与不合并PH的SSc患者相比,合并PH的SSc患者生存功能显著降低。在不同类型的PH中,SSc患者生存率最差,这突出了根据当前既定方法检测和评估PH的预后意义。